CapsoVision, Inc.

CapsoVision, Inc.

CVNYSE / NASDAQHealthcareSmall cap

$6.11-$0.20 (-3.2%)

Last close · Data as of Nov 20, 2026

Market cap
$376.7M
P/E
-14.9x
EV / EBITDA
-14.7x
Revenue
$13.6M
Net margin
-186.8%
ROCE
-185.7%

+14.6% over the last year

CapsoVision, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-8.5%
3M
+3.4%
6M
-5.7%
1Y
+14.6%
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change -$0.20 (-3.2%) from $6.31 to $6.11 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CV, bought on each weekday since 2025.

News & filings

What CapsoVision filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 25.3 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 15.3% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system.

Read moreShow less

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.

Sector
Healthcare
Shares outstanding
46.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$376.7M
P/E
-14.9x
P/B
28.4x
EV / EBITDA
-14.7x
EV / Sales
27.1x
P/S
27.8x
52-week high
$14.42
52-week low
$4.64

Profitability

Operating margin
-188.3%
Net margin
-186.8%
EBITDA margin
-184.1%
ROE
-190.9%
ROCE
-185.7%
ROIC
-499.6%
ROA
-139.4%
Asset turnover
0.75

Growth

Revenue
$13.6M
Revenue growth, 1Y
15.3%
Net profit growth, 1Y
27.2%
Free cash flow
-$23.0M

Solvency

Current ratio
3.77
Debt / Equity
0.07
Debt / Assets
0.05
CFO / Net profit
0.90
Cash / Market cap
2.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$13.6M
Cost of revenue$6.4M
Gross profit$7.2M
Operating expenses$32.7M
Research and development$18.3M
Selling, general and administrative$14.4M
Operating income-$25.5M
Interest and other$230.0k
Pretax income-$25.3M
Tax and other$30.0k
Net income-$25.3M

Revenue and net profit

Revenue grew 15.3% in FY2025; net profit is the dashed line.

CapsoVision, Inc. revenue and net profit by fiscal year
CapsoVision, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2023$9.8M-$11.3M
FY2024$11.8M-$19.9M
FY2025$13.6M-$25.3M

Cash flows

FY2025: -$22.9M from operations, -$23.0M free after investment (dashed).

CapsoVision, Inc. operating and free cash flow by fiscal year
CapsoVision, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2023-$10.8M-$11.6M
FY2024-$20.1M-$20.2M
FY2025-$22.9M-$23.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$13.6M+15.3%1Y
EBITDA
-$24.9M
Net profit
-$25.3M
Cash from operations
-$22.9M
Free cash flow
-$23.0M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$13.6M-$24.9M-$25.3M-$23.0M-190.9%+15.3%+27.2%

Monthly returns

Month-by-month returns of CV across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$18.2M
Liabilities$4.9M
Equity$13.3M
Paid-in capital$168.9M
Retained earnings-$155.7M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CV highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. CapsoVision, Inc. (this company)27.1x

Not shown (no positive earnings and no EV / Sales): Compass Therapeutics, Inc., Benitec Biopharma Inc., Lexeo Therapeutics, Inc., Perspective Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
CapsoVision, Inc.CVthis company$376.7M-14.9x28.4x-190.9%-14.7x
OmniAb, Inc.OABI$385.6M-6.0x1.4x-24.3%-8.1x
Compass Therapeutics, Inc.CMPX$383.6M-5.8x1.9x-33.8%-5.1x
Benitec Biopharma Inc.BNTC$379.6M-10.0x3.9x-39.0%-6.8x
Viemed Healthcare, Inc.VMD$377.2M25.3x2.7x10.6%7.4x
Vanda Pharmaceuticals Inc.VNDA$375.8M—1.1x-67.4%—
Lexeo Therapeutics, Inc.LXEO$375.3M-3.8x1.5x-40.5%-3.3x
Delcath Systems, Inc.DCTH$372.5M138.0x3.3x2.4%327.0x
Perspective Therapeutics, Inc.CATX$370.7M-3.6x1.8x-49.8%-3.4x
Peer median—-3.8x1.9x-36.4%-3.4x

Year-to-date ROI

CV since 1 January, against earlier years.

Historical volatility

CV's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

CapsoVision, Inc. operating margin by fiscal year
CapsoVision, Inc. operating margin by fiscal year
DateOperating margin
FY2023-116.4%
FY2024-169.4%
FY2025-188.3%
LineFY2025
Cost of revenueCost Of Revenue$6.4M
Gross profitGross Profit$7.2M
Operating expensesOperating Expense$32.7M
Research and developmentResearch And Development$18.3M
Total expensesTotal Expenses$39.1M
Pretax incomePretax Income-$25.3M

Learn while you research

Academy chapters picked for CapsoVision, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →